Substrate-dependent dynamics of UDP-galactopyranose mutase: Implications for drug design. 2013

Leonardo Boechi, and Cesar Augusto F de Oliveira, and Isabel Da Fonseca, and Karina Kizjakina, and Pablo Sobrado, and John J Tanner, and J Andrew McCammon
Department of Chemistry and Biochemistry, University of California San Diego, La Jolla, California.

Trypanosoma cruzi is the causative agent of Chagas disease, a neglected tropical disease that represents one of the major health challenges of the Latin American countries. Successful efforts were made during the last few decades to control the transmission of this disease, but there is still no treatment for the 10 million adults in the chronic phase of the disease. In T. cruzi, as well as in other pathogens, the flavoenzyme UDP-galactopyranose mutase (UGM) catalyzes the conversion of UDP-galactopyranose to UDP-galactofuranose, a precursor of the cell surface β-galactofuranose that is involved in the virulence of the pathogen. The fact that UGM is not present in humans makes inhibition of this enzyme a good approach in the design of new Chagas therapeutics. By performing a series of computer simulations of T. cruzi UGM in the presence or absence of an active site ligand, we address the molecular details of the mechanism that controls the uptake and retention of the substrate. The simulations suggest a modular mechanism in which each moiety of the substrate controls the flexibility of a different protein loop. Furthermore, the calculations indicate that interactions with the substrate diphosphate moiety are especially important for stabilizing the closed active site. This hypothesis is supported with kinetics measurements of site-directed mutants of T. cruzi UGM. Our results extend our knowledge of UGM dynamics and offer new alternatives for the prospective design of drugs.

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D011487 Protein Conformation The characteristic 3-dimensional shape of a protein, including the secondary, supersecondary (motifs), tertiary (domains) and quaternary structure of the peptide chain. PROTEIN STRUCTURE, QUATERNARY describes the conformation assumed by multimeric proteins (aggregates of more than one polypeptide chain). Conformation, Protein,Conformations, Protein,Protein Conformations
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013379 Substrate Specificity A characteristic feature of enzyme activity in relation to the kind of substrate on which the enzyme or catalytic molecule reacts. Specificities, Substrate,Specificity, Substrate,Substrate Specificities
D014349 Trypanosoma cruzi The agent of South American trypanosomiasis or CHAGAS DISEASE. Its vertebrate hosts are man and various domestic and wild animals. Insects of several species are vectors. Trypanosoma cruzus,cruzi, Trypanosoma
D014355 Chagas Disease Infection with the protozoan parasite TRYPANOSOMA CRUZI, a form of TRYPANOSOMIASIS endemic in Central and South America. It is named after the Brazilian physician Carlos Chagas, who discovered the parasite. Infection by the parasite (positive serologic result only) is distinguished from the clinical manifestations that develop years later, such as destruction of PARASYMPATHETIC GANGLIA; CHAGAS CARDIOMYOPATHY; and dysfunction of the ESOPHAGUS or COLON. Trypanosomiasis, South American,American Trypanosomiasis,Chagas' Disease,Trypanosoma cruzi Infection,Infection, Trypanosoma cruzi,Infections, Trypanosoma cruzi,South American Trypanosomiasis,Trypanosoma cruzi Infections,Trypanosomiasis, American
D014530 Uridine Diphosphate A uracil nucleotide containing a pyrophosphate group esterified to C5 of the sugar moiety. UDP,Uridine Pyrophosphate,Diphosphate, Uridine,Pyrophosphate, Uridine
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs

Related Publications

Leonardo Boechi, and Cesar Augusto F de Oliveira, and Isabel Da Fonseca, and Karina Kizjakina, and Pablo Sobrado, and John J Tanner, and J Andrew McCammon
March 2009, Proteins,
Leonardo Boechi, and Cesar Augusto F de Oliveira, and Isabel Da Fonseca, and Karina Kizjakina, and Pablo Sobrado, and John J Tanner, and J Andrew McCammon
February 2019, Journal of chemical information and modeling,
Leonardo Boechi, and Cesar Augusto F de Oliveira, and Isabel Da Fonseca, and Karina Kizjakina, and Pablo Sobrado, and John J Tanner, and J Andrew McCammon
February 2014, Archives of biochemistry and biophysics,
Leonardo Boechi, and Cesar Augusto F de Oliveira, and Isabel Da Fonseca, and Karina Kizjakina, and Pablo Sobrado, and John J Tanner, and J Andrew McCammon
August 2009, Journal of molecular biology,
Leonardo Boechi, and Cesar Augusto F de Oliveira, and Isabel Da Fonseca, and Karina Kizjakina, and Pablo Sobrado, and John J Tanner, and J Andrew McCammon
June 2013, Biochemistry,
Leonardo Boechi, and Cesar Augusto F de Oliveira, and Isabel Da Fonseca, and Karina Kizjakina, and Pablo Sobrado, and John J Tanner, and J Andrew McCammon
September 2004, Journal of the American Chemical Society,
Leonardo Boechi, and Cesar Augusto F de Oliveira, and Isabel Da Fonseca, and Karina Kizjakina, and Pablo Sobrado, and John J Tanner, and J Andrew McCammon
August 2006, Chemistry & biology,
Leonardo Boechi, and Cesar Augusto F de Oliveira, and Isabel Da Fonseca, and Karina Kizjakina, and Pablo Sobrado, and John J Tanner, and J Andrew McCammon
February 2003, Biochemistry,
Leonardo Boechi, and Cesar Augusto F de Oliveira, and Isabel Da Fonseca, and Karina Kizjakina, and Pablo Sobrado, and John J Tanner, and J Andrew McCammon
June 2004, Nature structural & molecular biology,
Leonardo Boechi, and Cesar Augusto F de Oliveira, and Isabel Da Fonseca, and Karina Kizjakina, and Pablo Sobrado, and John J Tanner, and J Andrew McCammon
October 2010, International journal of antimicrobial agents,
Copied contents to your clipboard!